Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089967 · ClinicalTrials.gov registry record
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 30
- Enrollment target
NCT06089967: Completed study, sponsored by Duke University.
NCT06089967 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06089967 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer. The body samples and health information will be stored for future research to understand more about side effects related to immune-based treatments for cancer.
Primary Outcome
Clinical database of participants receiving immune checkpoint inhibitors paired with biospecimen collection. Participant specimens are collected at time points before, during, and after cancer immunotherapy discontinuation. Clinical data collection includes, but is not limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, a
Interventions
- OTHER Medical chart review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2024-12-06 |
What the finished NCT06089967 record still lists
NCT06089967 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Medical chart review is the first listed.
NCT06089967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06089967 about?
NCT06089967 is a clinical study titled "Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy". The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer. The body samples and health information will be stored for future research to understand more about side effects related to immune-based treatm...
What is the current status of trial NCT06089967?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-10-05. Estimated completion is 2024-12-06.
What interventions are being tested in trial NCT06089967?
The interventions under investigation include: Medical chart review (OTHER).
Who is sponsoring clinical trial NCT06089967?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI